Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet® and AmBisome® in combination with caspofungin to rats infected with Aspergillus fumigatus

Journal of Pharmaceutical Sciences

Volumn 96, Issue 7, 2007, Pages 1737-1747

  Wasan, Kishor M ^a   Sivak, Olena ^a   Rosland, Michael ^a   Risovic, Verica ^a   Bartlett, Karen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ADME; Anti infectives; Disposition; Drug targeting; Lipids lipoproteins; Lipoplexes; Liposomes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; GALACTOMANNAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; MALE; MONOTHERAPY; MYCOSIS; NONHUMAN; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

EID: 34547203024     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20801     Document Type: Article

References (46)

1. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA. 1997. Pharmacokinetic profile of ABELCET (Amphotericin B Lipid Complex Injection): Combined experience from Phase I and Phase II studies. Antimicrob Agents Chemother 41:2201-2208.
2. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. 2003. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 97:1025-1032.
3. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46:245-247.
4. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. 1989. Analysis of the effect of liposomal encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81-86.
5. Bhamra R, Sa'ad A, Bolcsak LE, Janoff AS, Swenson CE. 1997. Behaviour of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 41:886-892.
6. Blom G. 1958. Statistical Estimates and Transformed Beta Variables. NY: John Wiley and Sons Inc. pp 1-58.
7. Bodey GP. 1986. Infection in cancer patients: A continuing association. Am J Med 81:11-26.
8. Chabot GG, Pazdur R, Valeriote FA, Baker LHH. 1989. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J Pharm Sci 78:307-310.
9. Elanjikal Z, Sorensen J, Schmidt H, Dupuis W, Tintelnot K, Jautzke G, Klingebiel T, Lehrnbecher T. 2003. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 22:653-666.
10. Franzot SP, Casadevall A. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 41:331-336.
11. Girmenia P, Martino P. 2003. New antifungal drugs and new clinical trials: Interpreting results may be difficult. Curr Opin Oncol 15:283-288.
12. Guo LS. 2001. Amphotericin B colloidal dispersion: An improved antifungal therapy. Adv Drug Deliv Rev 47:149-163.
13. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrobial Agents Chemotherapy 41:2339-2344.
14. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. 2001. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528-534.
15. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. 2003. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299.
16. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposomal- encapsulated amphotericin. B J Infect Dis 147:939-945.
17. Lopez-Berestein G, Rosenblum MG, Mehta R. 1984. Altered tissue distribution of amphotericin B by liposomal encapsulation: Comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1:199-205.
18. Lum LR, Turco TF, Leone J. 2002. Combination therapy with caspofungin and amphotericin B lipid complex. Am J Health Syst Pharm 59:80-81.
19. MacPhail GLP, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. 2002. Epidemiology, treatment and outcome of candidemia: A five-year review at three Canadian hospitals. Mycoses 45: 141-145.
20. Marr KA, Balajec SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. 2004. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables the affect performance. J Infect Dis 190:641-649.
21. Martin MT, Gavalda J, Lopez P, Gomis X, Ramirez JL, Rodriguex D, Len O, Jordano Q, Ruiz I, Rosal M, Almirante B, Pahissa A. 2003. Efficacy of high doses of Amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 52: 1032-1034.
22. Marty F, Mylonakis E. 2002. Antifungal use in HTV infection. Expert Opin Pharmacother 3:91-102.
23. Meyer RD. 1992. Current role of therapy with amphotericin B. Clin Infect Dis 14:S154-S160.
24. Ng AW, Wasan KM, Lopez-Berestein G. 2003. Development of liposomal polyene antibiotics: An historical perspective. J Pharm Pharm Sci 6:67-83.
25. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. 2002. Deeply invasive candidiasis. Infect Dis Clin North Am 16:821-835.
26. Perez-Soler R, Khokhar AR, Hacker MP, Lopez-Berestein G. 1986. Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocy- clohexane platinum (II) encapsulated in multilamellar vesicles. Cancer Res 46:6269-6273.
27. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46:12-23.
28. Pinker S. 2001. ORs closed after Aspergillus discovered at Royal Vic. CMAJ 164:1333.
29. Polak A. 2003. Antifungal therapy-state of the art at the beginning of the 21st century. Prog Drug Res Spec No 59-190.
30. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 28:49-61.
31. Ripeau JS, Aumont F, Belhumeur P, Ostrosky-Zeichner L, Rex JH, de Repentigny L. 2002. Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother 46:3096-3100.
32. Rothon DA, Mathias RG, Schechter MT. 1994. Prevalence of HIV infection in provincial prisons in British Columbia. Can J Med Assoc 151:S154-S160.
33. Segal BH, Bow EJ, Menichetti F. 2002. Fungal infections in nontransplant patients with hematologic malignancies. Infect Dis Clin North Am 16:935-964.
34. Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS, Wasan KM. 2004. Assessing the antifungal activity and toxicity profile of Amphotericin B Lipid Complex (ALBC; Abelcet®) in combination with Caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004 93:1382-1389.
35. St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G. 2001. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 39:949-953.
36. Swenson CE, Perkins WR, Roberts PR, Imran Ahmad I, Stevens R, Stevens DA, Janoff AS. 1998. In vitro and in vivo antifungal activity of amphotericin B lipid complex: Are Phospholipases important? Antimicrob Agents Chemother 42:767-771.
37. Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. 1982. Amphotericin B in liposomes: A novel therapy for histoplasmosis. Am Rev Respir Dis 125:610-611.
38. Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DR. 1991. Tissue distribution and in vivo immuno-suppressive activity of liposomal cyclosporine. Drug Metab Disp 19:1147-1151.
39. Voitl P, Scheibenpfiug C, Weber T, Janata O, Rokitansky AM. 2002. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 21:632-634.
40. Walsh TJ, Bacher J, Pizzo PA. 1988. Chronic silastic central venous catherization for reduction, maintenance and support of persistent granulocytopenia in rabbits. Lab Animal Sci 38:467-471.
41. Wasan KM, Grossie VB, Jr., Lopez-Berestein G. 1994. Concentrations in serum and Distribution in tissue of free and liposomal Amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother 38:2224-2226.
42. Wasan KM, Conklin JS. 1997. Enhanced Amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 24:78-80.
43. Wasan KM, Vadiei K, Lopez-Berestein G, Luke DR. 1990. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis 161:562-566.
44. Wasan KM, Kennedy AL, Cassidy SM, Ramaswamy M, Holtorf L, Chou JWL, Pritchard PH. 1998. Pharmacokinetics, distribution in serum lipoprotein and tissues and renal toxicities of Amphotericin B and Amphotericin B lipid complex in a hypercholesterolemic rabbit model: Single dose studies. Antimicrob Agents Chemother 42:3146-3152.
45. Wright JA, Bradfield SM, Park JR, Hawkins DS. 2003. Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases. J Pediatr Hematol Oncol 25:286-291.
46. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. 1999. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. CMAJ 160:493-499.